Identification of cetrimonium bromide and irinotecan as compounds with synthetic lethality against NDRG1 deficient prostate cancer cells

M.D. Wissing, J. Mendonca, E. Kim, J.S. Shim, N.S. Kaelber, H. Kant, H. Hammers, T. Commes, P.J. van Diest, J.O. Liu, S.K. Kachhap

Research output: Contribution to journalArticleAcademicpeer-review

Original languageUndefined/Unknown
Pages (from-to)401-410
JournalCancer Biology and Therapy
Issue number5
Publication statusPublished - 2013

Cite this